Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the second quarter ended June 30, 2023.
- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the second quarter ended June 30, 2023.
- The Company expects topline results from its Phase 1 trials, evaluating VRDN-001 and VRDN-003 SC in healthy volunteers, in the fourth quarter of 2023.
- As noted on the Company’s VRDN-001 Phase 1/2 data call in July, the Company will not be hosting a conference call to discuss its second quarter financial results.
- The Company will resume hosting a regular quarterly earnings call in November for its third quarter 2023 financial results.